Moderator: Dan Akschuti, Equity Partner, Pareto Securities

WELCOME ADDRESS

• Carl-Magnus Nesser, Ambassador, Embassy of Sweden in Bern
• Jan Larsson, CEO, Business Sweden
• Dan Akschuti, Equity Partner, Pareto Securities
• Noemi Rom, Head of Advisory, Networks and Strategy, Innosuisse
• Göran Håkansson, Market Head Nordics, Bank Vontobel

KEYNOTE SPEECHES

• Integrating Healthcare with Data Insights From Labs to Clinicians and Patients
  Igor Asner, Partnering Network Lead - Digital Health Products, Roche Diagnostics
  
  Synopsis: Digitalization plays an increasingly important role in delivering healthcare. Roche Diagnostics is actively developing digital solutions to support laboratory customers, clinicians in patients. This keynote will cover key elements of Roche's digital strategy and areas for potential partnerships and collaborations. 
  
  
• Partnering with Novartis
  Anu Balendran, Head of Transactions, Business Development & Licensing, Cardio Renal Metabolic, Novartis
  
  Synopsis: Novartis partnering brings together external innovation and the company’s scientific, development and commercial capabilities to advance differentiated medicines for patients. Its partnering priorities span four core therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; and oncology. These are supported by five technology platforms—chemistry, biotherapeutics, xRNA, radioligand therapy, gene and cell therapy—with opportunities considered across all stages of development.
  
  
• Increasing Sweden's Attractiveness for Clinical Trials
  Helena Lüning, Head of SweTrial
  
  Synopsis: Sweden has a strong tradition in clinical research, but competition for clinical trials is increasingly global. How can Sweden strengthen its position as an attractive destination for clinical trials? This presentation introduces SweTrial – a new national initiative bringing together healthcare, academia, industry, patients and public authorities – and how it aims to strengthen Sweden’s clinical trial ecosystem, improve national coordination and make Sweden easier to access for international partners

• The New Rules of Building Investable Biotech in Europe
  Bita Sehat, Partner and Head of Portfolio, Ventures, Trill Impact
  

  Synopsis: Europe remains one of the world’s strongest sources of scientific innovation, with exceptional research, talent and a long history of building important life science companies. Yet for decades, Europe has struggled to turn that scientific strength into globally scaled biotech companies, and recent shifts in capital markets, geopolitics, development timelines and global competition are making that challenge more acute. This keynote explores the new rules for building investable biotech in Europe, and what companies, investors and the broader ecosystem need to do differently to compete and scale globally.

• (TBC) Max Odlander, Partner, HealthCap
  
  
• Biotech Sector Trends
  Chien-Hsun Lee, Equity Research, Pareto Securities
  Dan Akschuti, Equity Partner, Pareto Securities
  
  Synopsis: Capital has returned to the sector this year, pushing major indices such as XBI and NBI to record levels. However, investors remain selective, running more concentrated portfolios and rewarding differentiated clinical data with sharp re-ratings and better financing access. M&A and licensing appetite is back, and AI is already now lifting capital efficiency and accelerating innovation across the life science industry.

PANEL DISCUSSION

• Mattias Gäreskog, Head of Life Science, Business Sweden (Moderator)
• Maria Groschopp Dellwik, Head of Listings Sweden, Nasdaq
• Anu Balendran, Head of Transactions, Business Development & Licensing, Cardio Renal Metabolic, Novartis
• Per Hedman, Partner, Cirio Advokatbyrå AB
• Kevin Maccabe, Senior Associate, Kellerhals Carrard

EUREKA / Eurostars: Boost innovation across boarders

• Janique Siffert, Program Manager, Innosuisse
• Johanna Scheck, Program Manager, FFG

COFFEE BREAK & NETWORKING

COMPANY PRESENTATIONS: INVESTOR & PARTNERING PITCHES

Room: Zurich 1 (Biotech):
Sponsored by Pharmaron

Moderator: Dan Akschuti, Equity Partner, Pareto Securities

10:15-10:55

Phamaron - Mathias Schacht
Hemispherian - Zeno Albisser
Discovery Evolution - Harold Vladar
Pilatus Bioscience - Raven Lin
Serial X - Yanyan Chen 

10:55-11:35

Circio - Erik Digman Wiklund 
Heartbeat Bio - Michael Krebs
Intervacc - Carl-Johan Dalsgaard 
Limula - Thomas Eaton
Sprint Bioscience - Johan Emilsson

11:35-12:10

Tridem Bioscience - Markus Mandler
Amphilix - Kevin McAllister
Solgate - Ariel Bensimon
Cinclus Pharma - Christer Ahlberg 
PharmNovo - Per von Mentzer

12:10-12:45

Bioversys - Marc Gitzinger 
Alzecure - Martin Jönsson
Abarceo Pharma - Adam Bruce
VeriGraft - Petter Björquist
Neurometa Therapeutics - Preben Bruun-Nyzell

Room: Zurich 2 (Medtech):

Moderator: Tugi Guenes Programme LeadStart-upEcosystem, Innosuisse

10:15-10:55

ArticZymes Technologies - Borge Sørvoll
Silkogen - Gabriel Tirouflet
Implantica - Peter Forsell 
Developeration - Johan Ungerstedt
Mentice - Frans Venker

10:55-11:35

Elyte Diagnostics - Andreas Fercher
Photocure - Dan Schneider 
Cordicity - Linus Ohlsson
Devyser - Jan Wahlström  
Nevarra Labs - Tobias Raffeiner
Senzime - Philip Siberg 

11:35-12:10

Nordic Kinetics - Jakob Gerstl
Alfred Surgery - Inger Jørstad
Reccan Diagnostics - Anna Broden
Genomill Health - Manu Tamminen
BioReperia - Emmelie Persson

NETWORKING LUNCH

ONE-TO-ONE MATCHMAKING MEETINGS

Pre-booked face-to-face meetings onsite in Zürich